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Summary. Background: Trauma-induced coagulopathy is
a complex multifactorial hemostatic response that is
poorly understood. Objectives: To identify distinct hemo-
static responses to trauma and identify key components
of the hemostatic system that vary between responses.
Patients/Methods: A cross-sectional observational study
of adult trauma patients at an urban level I trauma center
emergency department was performed. Hierarchical clus-
tering analysis was used to identify distinct clusters of
similar subjects according to vital signs, injury/shock
severity, and comprehensive assessment of coagulation,
clot formation, platelet function, and thrombin genera-
tion. Results: Among 84 total trauma patients included in
the model, three distinct trauma clusters were identified.
Cluster 1 (N = 57) showed platelet activation, preserved
peak thrombin generation, plasma coagulation dysfunc-
tion, a moderately decreased fibrinogen concentration and
normal clot formation relative to healthy controls. Clus-
ter 2 (N = 18) showed platelet activation, preserved peak
thrombin generation, and a preserved fibrinogen concen-
tration with normal clot formation. Cluster 3 (N = 9) was
the most severely injured and shocked, and showed a
strong inflammatory and bleeding phenotype. Platelet
dysfunction, thrombin inhibition, plasma coagulation dys-
function and a decreased fibrinogen concentration were
present in this cluster. Fibrinolytic activation was present
in all clusters, but was particularly increased in cluster 3.
Trauma clusters were most noticeably different in their
relative fibrinogen concentration, peak thrombin genera-
tion, and platelet-induced clot contraction. Conclusions:
Hierarchical clustering analysis identified three distinct
hemostatic responses to trauma. Further insights into the
underlying hemostatic mechanisms responsible for these
responses are needed.
Keywords: coagulation; fibrinogen; hemostasis; platelets;
thrombin; trauma.
Introduction
Trauma-induced coagulopathy (TIC) is an important and
incompletely understood multifactorial response to
trauma that is associated with increased bleeding, greater
transfusion requirements, and increased mortality [1].
Brohi et al. [2] first described spontaneous anticoagula-
tion according to an increase in the International Nor-
malized Ratio (INR) in the plasma of emergency
department (ED) trauma patients. Further work sup-
ported an anticoagulant mechanism resulting from a sys-
temic increase in the level of thrombomodulin, which,
when bound to thrombin, activated protein C [3]. Acti-
vated protein C (APC) can inhibit factor V and FVIII,
thus reducing thrombin generation. Fibrinolysis is also
enhanced by simultaneous inhibition of plasminogen acti-
vator inhibitor-1 (PAI-1) and increased plasma tissue-type
plasminogen activator (t-PA) levels [3,4]. Others have
stratified trauma patients according to disseminated intra-
vascular coagulopathy (DIC) score criteria, noting the
presence of an activated, rather than anticoagulated,
hemostatic state leading to DIC with a hyperfibrinolytic
phenotype [5]. There is also emerging evidence for a
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prominent role for platelet dysfunction in the pathomech-
anism of TIC. Even mildly impaired platelet aggregation
is strongly associated with poor outcomes in trauma
patients [6]. In addition, inflammation may play an
important role in modulating the acute coagulation
response to trauma and blood loss. Levels of the cyto-
kines interleukin (IL)-6 and tumor necrosis factor-a
(TNF-a) are elevated almost immediately after severe
injury and/or blood loss in trauma and surgical patients
[7]. An increased IL-6 level, in particular, is associated
with massive transfusion, the development of multiorgan
failure, and mortality [8]. IL-6 can also directly activate
fibrinogen gene promoters, thus linking its presence in
plasma directly to subsequent coagulation responses [9].
Endothelial activation is also a prominent component of
TIC, and may initiate coagulopathy after endothelial gly-
cocalyx shedding, allowing for direct interaction between
activated inflammatory cells and the endothelial surface
[10,11]. However, there is limited understanding of how
various components of the hemostatic and inflammatory
systems and injury/patient characteristics interact to pro-
duce overall hemostatic phenotypes after trauma.
Much of our current understanding of coagulopathy
after trauma comes from studies that grouped subjects
according to injury severity, shock severity, and/or single
estimates of coagulopathy, such as INR, viscoelastic clot
strength, or platelet aggregation. These approaches have
yielded significant knowledge regarding individual compo-
nents of the hemostatic response to trauma. However, the
information gained from these investigations is limited,
owing to selection bias, a priori assumptions about out-
come measures, and the chosen method of coagulopathy
classification. In addition, the generally accepted multifac-
torial nature of coagulopathy limits the ability of single
outcome measurements to adequately identify the syn-
drome of traumatic coagulopathy. Alternatively, data
mining techniques such as hierarchical clustering analysis
(HCA) can adequately identify distinct groups or pheno-
types within larger cohorts by grouping similar variables
and characteristics without requiring a priori assumptions.
HCA is a multivariate technique of grouping together
rows in a dataset that share similar values, and whose
values are close to each other relative to those of other
clusters. It is a process that starts with each point in its
own cluster; next, the two clusters that are closest
together are combined into a single cluster, until there is
only one cluster containing all of the points. This type of
clustering permits the detection of subgroups that would
otherwise be disguised, owing to high variation or a priori
assumptions [12]. HCA has been used successfully as a
data mining tool to identify blood plasma lipidomics pro-
files [13] and to identify complex metabolic states in criti-
cally injured patients [14]. The strategy of using HCA to
group patients by combining their clinical profiles with
broadly measured hemostatic parameters may be useful
to identify both distinct hemostatic responses and the
relationships governing these responses. Such information
can be used to improve our understanding of the patho-
physiology of TIC and to guide further studies.
The primary aim of this study was to use HCA to iden-
tify distinct hemostatic responses within a general trauma
patient cohort. We hypothesized that hierarchical cluster-
ing would identify multiple distinct hemostatic responses.
We also aimed to characterize the key differences between
clusters, and interpret how patient characteristics and
individual components of the hemostatic system interact
to produce an overall hemostatic response to trauma. To
this end, we applied HCA to a prospective cohort of
adult ED polytrauma patients who presented to a US
urban level I trauma center, and identified key differences
in hemostatic parameters between clusters.
Methods
This was a cross-sectional study of trauma patients
presenting to a US level I trauma center ED. Informed
consent was obtained from all subjects according to an
institutional human subjects review board-approved
protocol consistent with the Declaration of Helsinki. A
group of healthy non-injured volunteers who were not
taking anticoagulants were recruited from the local popu-
lation as a control group for comparison. Patients were
excluded if they were < 18 years of age, incarcerated,
pregnant, suicidal, or known to be taking anticoagulant
medications, including aspirin, clopidogrel, or warfarin.
To avoid confounding influences of blood transfusion or
massive non-survivable injury with a perimortem state,
patients were excluded if they received any blood products
prior to study sample blood draw, or were not expected to
live for 3 days, owing to obvious massive non-survivable
injury. The coagulation response in such perimortem
patients is often dominated by massive hyperfibrinolysis,
which would have added bias and skewed our data unnec-
essarily [15]. We also sought a mixed cohort of severely
injured trauma patients who would be more likely to vary
in their individual hemostatic responses. Therefore, we
excluded patients who were not expected to be admitted
to the inpatient trauma service, owing to isolated or minor
injury. Trauma patients were identified in the ED, and
blood was collected into standard citrated (1 : 9 ratio of
citrate to blood), EDTA and sodium–heparin vacutainers
prior to the patients receiving any blood products. Sam-
ples were collected on arrival at the ED prior to subjects
receiving any blood products, and blood was sampled
again 8 h later for repeat plasma coagulation and throm-
boelastography (TEG) measurements. Samples were either
processed immediately for viscoelastic clot formation,
platelet adhesion and platelet aggregation determination
in whole blood, fixed for flow cytometry analysis, or
centrifuged at 5000 9 g for 15 min to produce platelet-poor
plasma and frozen at  80 °C for later analysis. Clinical
data, including vital signs, transfusion requirements, inju-
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ries, clinical laboratory results, and outcomes, were col-
lected from the medical record for each patient. Injury
severity scores were obtained for each patient from the
hospital trauma databank.
Laboratory methods
Plasma coagulation Platelet-poor plasma was assayed
for INR, activated partial thromboplastin time (APTT)
and fibrinogen concentration with the START-4 coagula-
tion analyzer, according to the manufacturer’s instruc-
tions (Diagnostica Stago, Parsippany, NJ, USA).
Platelet function Adhesion of platelets under high flow
conditions was determined from time to occlusion of a
small orifice by use of the PFA-100 (Dade International,
Miami, FL, USA) with exposure to collagen/ADP. This
device measures time to occlusion of a small aperture as
whole blood is drawn through it under high-flow condi-
tions, and has been shown to respond to changes in pri-
mary platelet adhesion mediated by the glycoprotein (GP)
Ib–IX–V surface membrane complex in addition to von
Willebrand factor activity, and GPIIb/IIIa activation
[16,17]. Platelet aggregation was also determined from
impedance in whole blood (Chronolog Series 500 aggre-
gometer; Chrono-Log Corp., Havertown, PA, USA) in
response to ADP (10 lmol L1) to evaluate platelet
aggregation. Flow cytometry (BD Accuri C6; Accuri,
Ann Arbor, MI, USA) was used to measure platelet acti-
vation via the GP P-selectin, because it is rapidly translo-
cated to the platelet surface on stimulation. The P-selectin
content on the platelet surface was detected with the
CD62-P mAb conjugated with phycoerythrin (mouse
anti-human: BD Pharmingen, San Jose, CA, USA). We
also measured GPIIb/IIIa surface integrin transition to its
high-affinity state by using the mAb against high-affinity
glycoprotein IIb/IIIa platelet surface integrin (PAC-1)
conjugated with fluorescein isothiocyanate (BD Bioscienc-
es, San Jose, CA, USA). These assays provide an estimate
of the platelet activation state.
Viscoelastic measurements of whole blood clot forma-
tion TEG (TEG 5000; Haemonetics, Niles, IL, USA)
was used to measure whole blood viscoelastic clot forma-
tion. The TEG 5000 reports time to onset of clot forma-
tion (R), which positively correlates with thrombin
generation, the time needed to reach a predetermined level
of clot stiffness (K) and the angle (a-angle), which is the
clot formation rate and correlates with the fibrin genera-
tion rate, the maximal clot amplitude (MA) or stiffness,
and the percentage of clot breakdown resulting from fibri-
nolysis in the first 30 min after MA (LY30%). The TEG
with Platelet Mapping Assay (TEG-PM; Haemonetics)
was also used to determine the platelet contribution to clot
amplitude. Platelets were selectively activated with ADP,
and the amplitude difference between platelet-specific acti-
vation and maximal thrombin-induced clot formation dur-
ing TEG measurement was calculated and expressed as
percentage inhibition from MA.
Fibrinolytic activation and fibrinolysis We determined
clot lysis from TEG LY30% and fibrinolytic activation
from D-dimer measured by ELISA (Technozym D-
Dimer; Technoclone, Vienna, Austria). D-dimer is a
plasmin-specific cleavage product of fibrin.
Thrombin generation Thrombin generation profiles for
each subject were generated by the use of calibrated auto-
mated thrombography with a thrombin-specific fluorogen-
ic substrate (CAT; Thrombinoscope BV, Mastricht, The
Netherlands). Platelet-poor plasma was first activated
with low-level tissue factor (5 pmol) to activate thrombin
generation. The elapsed time from activation to onset of
thrombin generation (thrombin lag time), maximal throm-
bin concentration (Cmax) and area under the thrombin
generation curve (endogenous thrombin potential [ETP])
were recorded and included in the final analysis. Throm-
bin–antithrombin complexes were also measured in
plasma by ELISA (TAT micro; Siemens Healthcare
Diagnostics, Marburg, Germany).
Inflammation The cytokines IL-6 (Human IL-6 ELISA
Kit II; BD Biosciences) and TNF-a (Human TNF ELISA
Kit II; BD Biosciences) were measured in plasma by
ELISA, as estimates of the inflammatory response. Cell
counts, including leukocyte count as an estimate of
inflammation, and hemoglobin concentration were mea-
sured by automated cell counting in the research labora-
tory (ABX-60; Horiba, Irvine, CA, USA).
Statistical methods
Descriptive statistics (median and interquartile range
[IQR]) were used to summarize demographics and out-
come measurements, owing to significantly skewed data
distributions. Outcome variables included IL-6, TNF-a,
TEG parameters, categorical descriptions of injury sever-
ity, hemostatic transfusion thresholds, and blood prod-
ucts received. Clusters and control groups were then
compared by use of the non-parametric Kruskal–Wallis
test. Steel–Dwass adjustment was performed to adjust
for multiple comparisons for post hoc comparisons. Chi-
square analysis with likelihood ratio testing was used to
compare nominal outcomes between clusters. Matched-
pairs analysis was used to measure the mean difference
and 95% confidence interval of the difference between
the ED arrival sample and the 8-h sample for plasma
and TEG measurements.
Variables were selected for inclusion in the clustering
analysis if they were measured in ≥ 90% of subjects and
they represented an important component of clot forma-
tion (e.g. extrinsic and intrinsic pathways, fibrinogen,
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platelet activation and function, fibrinolysis, and inflam-
mation). Stringent HCA variable selection was used, lim-
iting the variables used to build the model to direct
laboratory measurements. We chose to not use any clini-
cal variables or subject characteristics (ISS, vital signs,
resuscitation fluid volumes, etc.) in the model. These clini-
cal and treatment variables have multiple colinear effects
on coagulopathy that have not yet been clearly defined,
making them poor contributors to independent cluster
selection. We also excluded TEG parameters (R, K, angle,
MA, and LY30%), because these measurements are
derived from one overall clot formation curve, and are
therefore strongly collinear, making them less useful for
clustering. Final variables included in the model were:
INR, APTT, fibrinogen concentration, thrombin lag time,
ETP, Cmax, platelet count, PFA-100 collagen/ADP clo-
sure time, ADP-activated platelet aggregation determined
by impedance, ADP-activated TEG-PM percentage inhi-
bition, PAC-1 (%), P-selectin (%), D-dimer, and leuko-
cyte count (white blood cells [WBCs]).
The purpose of HCA is to classify data of previously
unknown structure into discrete groups in an unbiased
fashion. The procedure starts by considering each obser-
vation, or subject, as a single cluster, and applying the
model-specific selection criteria for merging of adjacent
clusters for each variable assigned to the model. Model-
based HCA then proceeds by successively merging pairs
of clusters until all subjects are clustered together [18].
Ward’s minimum variance method was compared with
average linkage, complete linkage and centroid linkage
models. Ward’s minimum variance method uses classifica-
tion likelihood, based on the sum-of-squares, when com-
paring variables to assign subjects to clusters according to
their similarity to one another. The distance between two
clusters is the ANOVA sum of squares between the two
clusters added up over all the variables. Average linkage
uses the average distance between pairs of observations to
join clusters, and is slightly biased towards producing
clusters with the same variance. Complete linkage uses
the maximum distance between a subject in one cluster
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Fig. 1. Selection of appropriate model for hierarchical analysis. (A) Heat map and dendrogram of hierarchical clustering analysis, showing the
left-to-right clustering of individual subjects into separate clusters based on the similar values for each test variable. The results of analysis with
a three-cluster (HC1–HC3) Ward method are shown. (B) Selection of the best hierarchical clustering model by use of the Bayesian information
criterion (BIC) plotted against number of clusters. The Ward method produced the highest BIC with the least number of clusters, and was
selected over other models. (C) Discriminant analysis canonical plot of the three-cluster Ward model. Good discrimination between clusters
was possible, with misclassification of only four subjects (open circles). Cluster 1 (red) and cluster 2 (blue) were more similar, whereas cluster 3
(green) was clearly discriminated. Larger ellipses identify the area in which 50% of the subjects are found for each cluster. Smaller ellipses iden-
tify the 95% confidence interval for the center point of each cluster.
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and a subject in the other clusters to link clusters, and
tends to produce clusters with roughly equal diameters
that are susceptible to the influence of outliers. The cen-
troid method uses the squared Euclidean distance between
subject means to link clusters. The centroid method is
more robust to the influence of outliers. A procedure out-
lined by Fraley and Raftery, based on identifying the
model with the highest Bayesian information criterion
with the least number of clusters for each proposed
model, was used to select the best-performing model,
which was then used for HCA [19]. After model selection
and clustering, discriminant analysis was used to confirm
that the selected model demonstrated an acceptable
degree of separation between clusters, with minimal
misclassifications. All statistical analyses were performed
with JMP statistical software (version 9.0.0: SAS Institute,
Cary, NC, USA). The overall level of significance for all
statistical tests was P < 0.05.
Results
One hundred and sixty-three trauma subjects were
screened for enrollment. Forty-nine subjects were immedi-
ately excluded because they either declined to participate
(N = 16), had known anticoagulant use (N = 5), had
received blood products prior to blood sampling (N = 2),
or for other reasons (N = 26). Additional subjects were
excluded prior to HCA because they had incomplete data
(N = 6), or were not expected to survive for at least 72 h
(N = 9). A total of 99 trauma subjects met the clinical
Table 1 Demographics, injury profiles, and mortality
Healthy
controls
Injured subjects
Cluster 1 Cluster 2 Cluster 3
Age (years),
median (IQR)
41 (29–46) 30 (24–50) 52 (30–58) 36 (21–62)
Mean body
mass index
(IQR)
22 (20–26) 25 (23–28) 28 (24–32) 26 (20–29)
Prehospital
transport
time (min)
(IQR)
NA 42 (21–59) 34 (21–60) 30 (19–38)
N 10 57 18 9
Male gender,
n (% of total)
6 (60) 49 (86) 16 (89) 5 (55)
Injury category,
n (%)
Penetrating NA 15 (26) 5 (28) 2 (22)
Blunt NA 40 (70) 13 (72) 7 (78)
Both NA 2 (4) 0 0
Cause of injury,
n (%)
Stab wound NA 0 1 (6) 0
Gunshot wound NA 14 (25) 4 (22) 2 (22)
Motor vehicle
crash
NA 31 (54) 11 (61) 5 (56)
Pedestrian
struck by motor
vehicle
NA 7 (12) 2 (11) 2 (22)
Fall NA 5 (9) 0 0
Traumatic brain
injury
NA 17 (30) 2 (11) 5 (55)
72-h mortality NA 2 (3.5) 1 (5.6) 4 (44)
IQR, interquartile range; NA, not applicable.
Table 2 Initial emergency department vital signs, injury severity and 8-h fluid resuscitation for injured subjects
Vital signs
Cluster 1 Cluster 2 Cluster 3
Median IQR Median IQR Median IQR
Systolic blood pressure (mmHg) 120 111–142 146 117–165 93 76–124
Diastolic blood pressure (mmHg) 78 64–90 80 62–100 58 48–91
Respiratory rate (breaths min1) 18 14–24 18 15–22 20 16–29
Pulse (beats min1) 100 80–117 95 76–108 101 77–144
Anatomic injury severity
Injury Severity Scale 19 14–27 14 10–29 41*,† 28–49
Glasgow Coma Scale 15 3–15 15 14–15 3† 3–11
Shock severity
Lactate (mmol L1) 4.0 2.8–5.3 2.9 1.9–4.8 2.1 1.2–7.1
Base deficit (meq L1) 2.8 6.0 to 1.0 0.9 2.7 to 1.1 8.1*,† 16.2 to 5.0
Hemoglobin concentration (g dL1) 12.5 10.8–13.7 12.1 10.8–13.7 9.3* 6.2–12.0
Resuscitation fluid volume (mL)
Crystalloid at time of sampling 1400 500–2000 500 0–2000 2000 1350–2300
Crystalloid at 8 h 1169 486–2599 346 56–2000 3240† 2195–7075
Blood products at 8 h (mL)
Packed red blood cells 0 0–465 0 0–310 2325*,† 310–6433
Fresh frozen plasma 0 0–0 0 0–0 1350*,† 169–3251
Platelet concentrate 0 0–0 0 0–0 100*,† 0–350
Cryoprecipitate 0 0–0 0 0–0 215*,† 38–633
IQR, interquartile range. Non-parametric multiple comparisons with Steel–Dwass all-pairs adjustment for individual differences. *Difference
versus cluster 1, P < 0.05. †Difference versus cluster 2, P < 0.05.
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inclusion criteria and were considered for HCA analysis.
They were compared with 10 healthy uninjured volunteer
control subjects, who were enrolled separately.
The Ward three-cluster model was chosen as the best-
performing model for HCA of this dataset (Fig. 1B). A
total of 99 subjects and 14 variables were entered into the
model for clustering. The total number of missing values
was 28 of 1386 (1.7%). Owing to the missing values, 84
of 99 (85%) subjects entered into the model could be
clustered. The variable with the most missing values was
TEG-PM percentage inhibition, with seven of 99 (7%) of
values missing. The resulting HCA showed three distinct
clusters. According to the dendrogram, cluster 1 (N = 57)
and cluster 2 (N = 18) were in closer proximity to each
other than to cluster 3 (N = 9), which was located further
away and was more distinct. The dendrogram and heat
map generating the three clusters are shown in Fig. 1.
Smaller subclusters present in the dendrogram were not
evaluated, owing to small sample numbers.
Demographics, injury patterns, shock severity and mor-
tality for each cluster are shown in Table 1. Note that no
subjects received hemostatic agents, including tranexamic
acid, prior to the ED or 8-h blood samples being obtained.
Overall mortality measured 72 h after hospital admission
for those included in clustering was seven of 84 (8%); of
these, one subject died before 8 h, and this subject was
assigned to cluster 2. Subjects were mostly middle-aged
males with normal to overweight body composition. For
each cluster, blunt injury from motor vehicle crashes was
the primary mechanism of injury, followed by penetrating
injury from gunshot wounds. The prevalence of traumatic
brain injury was also increased in cluster 3.
Vital signs, shock severity and fluid resuscitation char-
acteristics are given in Table 2 and Fig. 2. Cluster 3
showed significantly abnormal vital signs, greater injury,
and greater shock. Cluster 3 also clearly required more
crystalloid and blood products over the first 8 h of hospi-
tal treatment. Significantly more subjects met fibrinogen
replacement criteria in cluster 1 than in cluster 2
(Fig. 2B).
Hemostatic and inflammatory parameters are shown in
Table 3. Again, cluster 3 showed the strongest bleeding
phenotype, with significantly different plasma coagulation
pathway test results, fibrinogen concentration, thrombin
generation, and platelet dysfunction, and increased levels
of inflammatory markers. Interestingly, cluster 1 differed
from healthy controls and cluster 2 by a slight prolonga-
tion of the INR, a moderate decrease in fibrinogen con-
centration, strongly inhibited platelet-induced clot
contraction, and an increased WBC count.
Injury, shock severity, and mortality
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Fig. 2. Characterization of subjects in each cluster. (A) Histogram of
nominal categories for injury severity, shock severity and mortality
for each cluster. There was significantly more profound injury and
hemorrhagic shock in cluster 3 than in clusters 1 and 2. Seventy-
two-hour mortality was also greatest in cluster 3, but statistical
analysis of a comparison with other clusters was not possible, owing
to the low number of non-survivors in the other clusters. (B) Histo-
gram of the prevalence of standard hemostatic transfusion thresholds
present in each cluster. **Criteria from [20]. (C) Histogram of preva-
lence of subjects receiving blood products within the first 8 h of hos-
pitalization by cluster (N = 68). Subjects were counted if they
received any amount of specified blood product. Hemostatic transfu-
sion was defined as the receipt of any amount of fresh frozen
plasma, platelet concentrate, or cryoprecipitate. Chi-square
likelihood ratio: *P < 0.05 versus cluster 1; †P < 0.05 versus
cluster 2. APTT, activated partial thromboplastin time; INR,
International Normalized Ratio.
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Plasma coagulation and TEG parameters measured at
ED arrival and again after 8 h of hospitalization are
shown in Table 4, and the interval changes for each
parameter over 8 h of hospitalization are shown in Fig. 3.
At ED arrival, cluster 3 showed impaired clot formation,
as demonstrated by a significantly prolonged K, a
decreased angle and decreased MA as compared with
other clusters. Note that there were no differences in clot
onset time (R), even though extrinsic and intrinsic plasma
pathway tests showed significant prolongation. At 8 h,
the greatest changes were normalization of the INR and
APTT, an increased fibrinogen concentration and
decreased clot lysis with concurrent normalization of
other TEG parameters in cluster 3. No measured parame-
ters changed significantly over 8 h in cluster 1 or cluster 2
(Fig. 3).
Discussion
Application of HCA to this selected trauma cohort
revealed three distinct hemostatic responses to injury. Our
results agree with previous characterizations of TIC show-
ing that overt coagulopathy was most often present in
those patients with severe anatomic injury and tissue hyp-
operfusion resulting from hemorrhagic shock [2]. These
patients also required more blood transfusions and were
the most likely to die. It is clear that the most severely
injured and shocked patients (cluster 3) showed a
profoundly decompensated and impaired hemostatic
and proinflammatory response that required significant
hemostatic therapy. However, trauma patients have
traditionally been stratified into only coagulopathic or
non-coagulopathic groups. Only more recently have inves-
tigators identified a third acute hypercoagulable or acti-
vated hemostatic state as also existing in ED trauma
patients. Branco et al. found that coagulation activation
was associated with less blood product transfusion and
low mortality, and was therefore protective during the
acute phase of trauma treatment [21]. Similarly, we also
identified a small cluster of subjects (cluster 2) with an
overall activated hemostatic response that required mini-
mal hemostatic therapy during the acute phase of trauma
treatment (i.e. the first 8 h of hospitalization). Increas-
ingly, it appears that an acutely activated hemostatic
response may be optimal to reduce blood loss, and that
any impairment of this activated state may signal an
increased risk of bleeding. This concept is supported by
evidence that even a minor prolongation of the INR
(> 1.2) into what most providers accept as being the ‘low
normal’ range is associated with increased mortality in
trauma patients [22].
The majority of subjects in this cohort (58%, cluster 1)
showed a distinct compensated initial hemostatic state
with viscoelastic clot formation that was not significantly
abnormal. This largest subgroup represents a newly rec-
ognized and important group of trauma patients, and its
presence helps to bridge the previously identified prohe-
mostatic and bleeding responses to trauma. The hemo-
static components that were most different between
cluster 1 and cluster 2 were fibrinogen concentration and
the relative platelet activation state. Hagemo et al.
showed that 229 mg dL1 fibrinogen was the threshold
Table 4 Plasma coagulation and thrombelastography measurements at emergency department (ED) arrival and after 8 h of hospitalization for
each cluster
Cluster 1 Cluster 2 Cluster 3
Plasma coagulation Measurement time Median IQR Median IQR Median IQR
INR ED arrival 1.2 1.1–1.4 1.1 1.1–1.3 2.0*,† 1.8–2.7
8 h 1.2 1.1–1.3 1.1 1.1–1.3 1.3 1.2–1.4
APTT (s) ED arrival 32.0 29.6–35.7 31.0 28.7–34.2 53.0*,† 48.3–77.3
8 h 34.0 30.3–37.0 34.5 30.4–38.3 38.6 33.1–45.1
Fibrinogen (mg dL1) ED arrival 220 175.6–322.1 285 216.8–359.3 113.2*,† 100.0–129.8
8 h 238.9 206.8–307.2 265.0 241.7–361.8 209.5 152.1–321.0
TEG clot formation
R (min) ED arrival 4.3 3.3–5.1 4.2 3.4–4.8 4.6 4.2–6.0
8 h 4.8 4.2–5.7 4.8 3.1–5.8 4.6 3.9–5.2
K (min) ED arrival 1.4 1.2–1.6 1.2 1.1–1.6 2.2*,† 1.6–3.1
8 h 1.4 1.2–1.8 1.3 1.1–1.8 1.9 1.2–2.4
ANG (°) ED arrival 70.2 66.2–72.9 71.2 64.9–74.3 61.7*,† 52.2–67.5
8 h 69.7 63.6–71.6 70.0 63.5–73.6 65.1 58.8–71.6
MA (mm) ED arrival 61.7 57.7–65.6 61.9 60.2–68.0 51.5*,† 45.2–60.8
8 h 61.7 58.2–64.8 64.3 60.0–65.6 57.2 53.6–64.0
LY30% ED arrival 0.3 0.0–1.4 0.8 0.3–2.5 0.0 0.0–1.6
8 h 0.1 0.0–0.8 0.4 0.0–1.6 0*,† 0.0–0.0
ANG, clotting angle; APTT, activated partial thrombplastin time; INR, International Normalized Ratio; IQR, interquartile range; K, clot for-
mation time; LY30%, percentage clot lysis at 30 min; MA, maximal clot amplitude; R, clot onset time; TEG, thromboelastography. Non-para-
metric multiple comparisons with Steel–Dwass all-pairs adjustment for individual differences. *Difference versus cluster 1, P < 0.05.
†Difference versus cluster 2, P < 0.05.
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Fig. 3. Box and whisker plots of average percentage changes in coagulation and thrombelastography (TEG) measurements when measured at
emergency department arrival and again after 8 h of hospitalization. Whiskers represent the 5th and 95th percentiles. Plots that do not include
zero represent statistically significant changes at a = 0.05. APTT, activated partial thromboplastin time; INR, International Normalized Ratio;
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for mortality in a recent multicenter observational study
[23]. The fibrinogen concentration in cluster 1
(median 220, IQR 175.6–322.1) mirrored this critical
threshold, theoretically placing this cluster at risk for
increased mortality. D-dimer levels were also elevated,
suggesting that significant fibrinolytic activation and
ADP-specific clot contraction was also severely impaired.
However, overall clot formation was not impaired.
Perhaps subtle changes in clot formation were
obscured in kaolin-activated TEG. However, according to
the cell-based model of hemostasis, small increases in
plasma thrombin can activate platelets prior to the more
dramatic ‘thrombin burst’ at the platelet surface [24].
Therefore, it is logical that preserved maximal plasma
thrombin generation after tissue factor activation was
seen concurrently with preserved platelet adhesiveness
and aggregation in clusters 1 and 2. Platelet adhesiveness
under high shear (PFA-100 collagen/ADP closure time)
was enhanced in these clusters, even though there was no
concurrent increase in PAC-1 or P-selectin binding, sug-
gesting that either GPI–IX–V-dependent adhesion or von
Willebrand factor may have been activated to increase
adhesiveness. Preserved platelet reactivity appears to be
critical, because platelet aggregation defects, even within
the low normal range, are strongly associated with mor-
tality in trauma patients [6]. A similar trend towards
shortened high-shear closure times with the PFA-100 was
found by Jacoby et al. when comparing trauma patients
with healthy controls, indicating a degree of platelet acti-
vation after injury [25]. The preserved maximal thrombin
generation in plasma in cluster 1 may have supported
adequate platelet adhesion/aggregation and clot forma-
tion in spite of fibrinolysis with moderate fibrinogen
depletion.
All trauma clusters in this cohort showed significant
fibrinolytic activation by D-dimer as compared with
normal healthy controls. D-dimer levels were lowest in
cluster 2, and were relatively increased nearly four-fold
in cluster 1 and six-fold in cluster 3. These differences
were not statistically significant, probably because of the
limited sample size. However, this trend does lend sup-
port to different degrees of fibrinolytic regulation after
trauma. Moore et al. recently obtained similar results, in
which three distinct clot lysis responses were seen in
trauma patients, one of which was fibrinolytic shutdown
[26]. Using D-dimer, we found that lysis was reduced,
but not abolished, in cluster 2 as compared with healthy
controls. Interestingly, ADP-activated TEG-PM was also
normal in this cluster, suggesting that adequate platelet-
induced clot contraction may also contribute to fibrino-
lytic resistance after trauma. Nevertheless, fibrinolytic
activation was present and associated with coagulopathy,
possibly because of either the presence of fibrin formed
at injured tissue, an increased t-PA concentration
resulting from endothelial release, or PAI-1 inhibition by
APC [3–5].
Limitations
This study is limited in several ways. The primary limita-
tion is its small sample size. This was primarily because
we limited the study to severely injured trauma patients
who could yet be saved. Thus, the exclusion of massively
injured subjects who were not expected to live regardless
of treatment may have minimized the effects of fibrinoly-
sis in this cohort, and other cohorts may not cluster simi-
larly. We can also only provide associations between
measured parameters, and cannot infer causality from this
study. The use of kaolin-activated TEG may also have
obscured subtle changes in TEG R, thus affecting our
interpretation of the results. We also did not measure
components of the protein C pathway or endothelial acti-
vation and/or dysfunction in this study. Understanding
these components is critical for understanding the bio-
chemical response to trauma and bleeding after trauma,
and they should be incorporated in future HCA efforts.
Another limitation is retained colinearity between the
variables selected for HCA. Specifically, multiple tests of
the platelet ADP receptor activation response may have
added bias to the clustering results. Clustering may also
have been affected by the exclusion of subjects who were
not expected to live for 72 h. This exclusion criterion
introduces a degree of survival bias that should be consid-
ered when these results are generalized. This is the initial
attempt at HCA in an undifferentiated trauma cohort
that provides new insights into the various hemostatic
responses to trauma. Therefore, our results require fur-
ther confirmation in larger trauma cohorts. In addition,
further specific analyses of the behavior of the individual
hemostatic and inflammatory components measured in
this study are required and are underway.
Conclusion
HCA identified three types of distinct hemostatic response
in ED trauma patients. Further investigations into hemo-
static mechanisms after trauma are warranted.
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